ACC.23 In a multisite-RCT study was examined whether an intervention including individualized reminders sent to primary care clinicians improved use of high-intensity statin in patients with ASCVD.

ACC.23 In the COORDINATE-Diabetes trial was investigated whether a multifaceted intervention can improve prescription of 3 groups of evidence-based therapies in patients with T2DM and ASCVD.

ACC.23 Among men aged 45 to 70 years without CV risk factors, lifelong endurance athletes have a higher coronary plaque burden compared to participants who exercise up to 3 hours per week.

ACC.23 Injectable treatments may have poor adoption due to access barriers and the need for repeat injections. An oral PCSK9 inhibitor, MK-0616, was developed and tested in a phase 2b trial.

ACC.23 UK Biobank participants who followed a low-carbohydrate high-fat diet had higher LDL-c and apoB levels and an increased risk of incident MACE compared with those on a standard diet.

ACC.23 An EHR-embedded and selective alert delivered during the clinical encounter increased the likelihood of prescribing MRA by 2.5x in MRA-eligible HFrEF patients in an outpatient cardiology setting.

ACC.23 The CLEAR Outcomes study showed that among statin-intolerant primary and secondary prevention patients, bempedoic acid reduced the risk of the primary composite endpoint of nonfatal MI, nonfatal stroke, coronary revascularization or CV death.

The European Commission has approved dapagliflozin to extend the indication to cover HF patients across the full range of LVEF (now including HFmrEF and HFpEF).

In a post-hoc analysis of the ADVANCE trial, cumulative SBP load was a better predictor of the occurrence of MACE in patients with T2DM compared with other BP measures.

A Dutch cross-sectional study showed that Lp(a) levels were higher and more often elevated in children with a clinical presentation of FH in whom no FH-causing mutation was detected compared with children with a mutation and their unaffected siblings.

A Norwegian nationwide cohort study showed that in newly diagnosed HF patients, 1-year adherence to dual or triple HF therapies was low and 2- to 5-year persistence was inadequate.

Sufficient physical activity lowers the risk of CV mortality and improves quality of life. However, little is known about the association between timing of physical activity and CVD risk in the general population.